December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Dose-dependent Neuroprotective Effects Of Brimonidine Against Ischemia-induced Retinal Ganglion Cell Death
Author Affiliations & Notes
  • MP LaFuente
    Departamento de Oftalmologia Universidad de Murcia Murcia Spain
  • MP Villegas-Pérez
    Departamento de Oftalmologia Universidad de Murcia Murcia Spain
  • S Mayor-Torroglosa
    Departamento de Oftalmologia Universidad de Murcia Murcia Spain
  • ME Aguilera
    Departamento de Oftalmologia Universidad de Murcia Murcia Spain
  • J Miralles de Imperial
    Departamento de Oftalmologia Universidad de Murcia Murcia Spain
  • M Vidal-Sanz
    Departamento de Oftalmologia Universidad de Murcia Murcia Spain
  • Footnotes
    Commercial Relationships    M.P. LaFuente, Allergan Inc F; M.P. Villegas-Pérez, Allergan Inc. F; S. Mayor-Torroglosa, Allergan Inc. F; M.E. Aguilera, Allergan Inc. F; J. Miralles de Imperial, Allergan Inc. F; M. Vidal-Sanz, Allergan Inc. F. Grant Identification: F.Seneca PI82/540/FS01, FIS99/1090 and Allergan
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 765. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      MP LaFuente, MP Villegas-Pérez, S Mayor-Torroglosa, ME Aguilera, J Miralles de Imperial, M Vidal-Sanz; Dose-dependent Neuroprotective Effects Of Brimonidine Against Ischemia-induced Retinal Ganglion Cell Death . Invest. Ophthalmol. Vis. Sci. 2002;43(13):765.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To investigate in adult Sprague-Dawley rats the neuroprotective effects of different concentrations of topically applied Brimonidine(BMD) on retinal ganglion cell (RGC) survival, short and long periods of time after transient ligature of the ophthalmic vessels (LOV). Methods: RGCs were labeled with Fluorogold (FG) applied to both superior colliculi. Seven days later, the left ophthalmic vessels were ligated for 90 minutes. The left eyes were treated topically 1 hour before retinal ischemia with two 5µl drops of saline alone or saline containing 0.0001, 0.001, 0.01 or 0.1% BMD. Rats were analyzed 7, 14 or 21 days later, and RGC survival was estimated by counting FG-labelled cells in 12 standard areas of both ischemic and contralateral non-ischemic retinas. Results: i) Seven days after 90 minutes of transient ischemia and topical pre-treatment with saline there was loss of approximately 46% of the RGC population. At this time point, topical pre-treatment with BMD prevented ischemia-induced RGC loss in a dose-dependent manner. Administration of 0.0001% BMD had no significant neuroprotective effects. Administration of higher concentrations of BMD (0.001 or 0.01%) resulted in the survival of 76 or 90%, respectively, of the RGC population, and 0.1% BMD fully prevented RGC loss. ii) Between 7 and 21 days after ischemia, there was an additional loss of approximately 25% of the RGC population in the saline pre-treated eyes. Pre-treatment with 0.1% BMD also diminished significantly this slow RGC death. Conclusion: The neuroprotective effects of BMD, when administered topically, are dose-dependent. The 0.1% concentration achieves optimal neuroprotective effects in the first seven days after ischemia. This concentration is also effective in reducing the protracted loss of RGCs that occurs between 7 and 21 days after transient ischemia.

Keywords: 448 ischemia • 489 neuroprotection • 415 ganglion cells 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×